partnering

News

Paul Biondi of Flagship's Pioneering Medicines

Pfizer inks $7bn strategic level R&D deal with Flagship

Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne

News

Roche eyeing $7bn deal to buy Roivant drug; report

Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco

News

TIGIT underwhelms again as Novartis ducks out

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

Eiger wields axe as FDA sets high bar for hepatitis drug

Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud

News

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc

Pfizer inks $7bn strategic level R&D deal with Flagship

Roche eyeing $7bn deal to buy Roivant drug; report

TIGIT underwhelms again as Novartis ducks out

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Eiger wields axe as FDA sets high bar for hepatitis drug

Catalyst throws lifeline to Santhera with $90m Duchenne deal

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

partnering

Editor's Picks